Mirabegron
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Mirabegron: From Overactive Bladder (mechanism-inferred) to Thoracic Malformation
One-Sentence Summary
Mirabegron is a β3-adrenergic receptor agonist that mechanistically acts on bladder detrusor muscle and brown adipose tissue; no confirmed original indication or EU marketing authorization is recorded in this evidence pack. The TxGNN model’s top prediction is Thoracic Malformation (score 83.06%), but this is supported by zero clinical trials and zero publications, and the evidence pack’s own mechanistic review flags it as a likely knowledge-graph co-occurrence artifact rather than a genuine drug–disease relationship.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in regulatory data (mechanistic notes indicate action on bladder detrusor muscle, consistent with β3-agonist class use in overactive bladder) |
| Predicted New Indication | Thoracic Malformation |
| TxGNN Prediction Score | 83.06% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not currently marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Mirabegron’s original indication is not available in the evidence pack (flagged as a Data Gap, DG002, High severity). Based on the limited information present, Mirabegron is known as a β3-adrenergic receptor agonist acting primarily on bladder detrusor muscle and brown adipose tissue — consistent with the drug class typically used for overactive bladder, though this is not confirmed by any regulatory license text in this pack.
For the top-ranked prediction, thoracic malformation, the evidence pack’s own mechanistic analysis explicitly concludes there is no known receptor expression or signaling pathway link between β3-adrenergic agonism and thoracic skeletal developmental abnormality. It classifies this association as a statistical artifact arising from knowledge-graph embedding proximity rather than a genuine mechanism-derived hypothesis.
Notably, several other candidates in the top-10 list (rank 3: polycystic kidney/liver disease; ranks 6–7: esophageal varices) show similarly weak or even mechanistically contradictory rationale — e.g., β3-agonism activates cAMP signaling, which runs counter to the cAMP-lowering strategy used therapeutically in polycystic kidney disease (tolvaptan), and is pharmacologically opposite to the non-selective β-blockade used in esophageal varices management. No candidate in this evidence pack currently has a mechanistically well-supported rationale.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Note: A Blocking-severity data gap (DG001) has been identified — TFDA/regulatory-equivalent warnings and contraindications for Mirabegron are not available, which prevents this candidate from entering the S1 safety pre-screening stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (thoracic malformation) is an L5, model-only association with no clinical trial or literature support, and the evidence pack’s own mechanistic review identifies it as a likely spurious knowledge-graph correlation rather than a biologically plausible signal. Combined with a Blocking-severity safety data gap and the absence of confirmed EU marketing status, there is currently no basis to advance this candidate.
To proceed, the following is needed:
- TFDA/EMA-equivalent SmPC warnings and contraindications (resolves DG001, Blocking)
- Confirmed original indication and mechanism of action data (resolves DG002, High)
- Independent preclinical or mechanistic evidence linking β3-adrenergic agonism to thoracic malformation before this candidate can move beyond S0
- If pursuing alternative candidates from this pack (e.g., rank 3, polycystic kidney/liver disease), a pharmacological reassessment is needed given the cAMP-pathway directionality conflict noted in the rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.